129 Xenon MRI in Chronic Lung Disease
Subjects aged 18-85 with lung disease will undergo hyperpolarized Xenon 129 (129-Xe) MRI and Pulmonary Function testing for the development of tools to evaluate the Apparent Diffusion Coefficient (ADC), ventilation defect percent (VDP) and pulmonary gas exchange measurements obtained by analysis of hyperpolarized 129-X
| Condition(s) | Lung Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Subjects aged 18-85 with lung disease will undergo hyperpolarized Xenon 129 (129-Xe) MRI and Pulmonary Function testing for the development of tools to evaluate the Apparent Diffusion Coefficient (ADC), ventilation defect percent (VDP) and pulmonary gas exchange measurements obtained by analysis of hyperpolarized 129-Xe MRI. |
| Who can participate | Inclusion Criteria: * Subjects male and female aged 18-85 with diagnosed lung disease including but not limited to: asthma, emphysema, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, sarcoidosis, pulmonary fibrosis, alpha 1-anti-trypsin deficiency, and lymphangioleiomyomatosis (LAM) * Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent * Subject must be able to perform a breathhold for 16s. * Subject is judged to be in otherwise stable health on the basis of medical history * Subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have Forced Expiratory Volume at one second (FEV1) values that do not vary more than 5% of the largest value or more th |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Lead sponsor | Western University, Canada |
| Locations | London, Ontario, Canada |
| Start date | 2011-08 |
| NCT ID | NCT02723500 |
| Official listing | https://clinicaltrials.gov/study/NCT02723500 |